← Back to Search

Checkpoint Inhibitor

Pembrolizumab for Myelodysplastic Syndrome

Phase 1
Waitlist Available
Led By John Magenau, M.D.
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a cancer treatment for people with leukemia whose disease has returned after a stem cell transplant.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number of patients that demonstrate clinical benefit from treatment
The number of patients that experience Graft Versus Host Disease (GvHD) or other significant immune mediated toxicities
The number of patients that respond to treatment
Secondary outcome measures
The number of patients alive at 1 year
The number of patients alive at 1 year without disease

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: PembrolizumabExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
293 Previous Clinical Trials
24,081 Total Patients Enrolled
John Magenau, M.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
1 Previous Clinical Trials
46 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
2017. "Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03286114.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top